This presentation by Rouba Kozak, USA, was recorded on 20 January 2025 at the ECNP Roadmap Meeting on Precision Psychiatry in Frankfurt, Germany.
The talk discusses implementing precision medicine in R&D, using Alzheimer's disease as a case study, and introduces a new initiative for depression. It highlights the global burden of mental health disorders and the economic loss, emphasizing the need for a new drug development paradigm and stressing the importance of biomarkers in precision medicine for target engagement, patient selection, and monitoring responses. A large-scale initiative is proposed to generate standardized clinical datasets, define endophenotypes, and predict treatment responses. Initially small, it will scale based on outcomes, aiming to identify biomarkers for depression and other disorders. Future interventional studies may follow, depending on findings.
Views and opinions expressed in these videos are those of the presenters and do not necessarily reflect the official position of ECNP. The content of these videos should not be used in any way as the basis for treatment decisions.
